Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 88

1.

Bile acid metabolism is altered in multiple sclerosis and supplementation ameliorates neuroinflammation.

Bhargava P, Smith MD, Mische L, Harrington EP, Fitzgerald KC, Martin KA, Kim S, Reyes AAA, Gonzalez-Cardona J, Volsko C, Tripathi A, Singh S, Varanasi K, Lord HN, Meyers KR, Taylor M, Gharagozloo M, Sotirchos ES, Nourbakhsh B, Dutta R, Mowry E, Waubant E, Calabresi PA.

J Clin Invest. 2020 Mar 17. pii: 129401. doi: 10.1172/JCI129401. [Epub ahead of print]

2.

Socioeconomic status and race are correlated with affective symptoms in multiple sclerosis.

Wang Y, Tian F, Fitzgerald KC, Bhattarai JJ, Naismith RT, Hyland M, Calabresi PA, Mowry EM.

Mult Scler Relat Disord. 2020 Feb 14;41:102010. doi: 10.1016/j.msard.2020.102010. [Epub ahead of print]

PMID:
32088654
3.

Leveraging real-world data to investigate multiple sclerosis disease behavior, prognosis, and treatment.

Cohen JA, Trojano M, Mowry EM, Uitdehaag BM, Reingold SC, Marrie RA.

Mult Scler. 2020 Jan;26(1):23-37. doi: 10.1177/1352458519892555. Epub 2019 Nov 28.

4.

Conducting dietary intervention trials in people with multiple sclerosis: Lessons learned and a path forward.

Fitzgerald KC, Sand IK, Senders A, Spain R, Giesser B, Sullivan P, Baer DJ, LaRocca N, Zackowski K, Mowry EM.

Mult Scler Relat Disord. 2020 Jan;37:101478. doi: 10.1016/j.msard.2019.101478. Epub 2019 Oct 29. Review.

PMID:
31704546
5.

Pragmatic clinical trials for treating relapsing multiple sclerosis.

Mowry EM, Ontaneda D, Evangelou N, Newsome SD.

Lancet Neurol. 2019 Dec;18(12):1075. doi: 10.1016/S1474-4422(19)30386-2. No abstract available.

PMID:
31701890
6.

Evaluation of multiple sclerosis disability outcome measures using pooled clinical trial data.

Goldman MD, LaRocca NG, Rudick RA, Hudson LD, Chin PS, Francis GS, Jacobs A, Kapoor R, Matthews PM, Mowry EM, Balcer LJ, Panzara M, Phillips G, Uitdehaag BMJ, Cohen JA; Multiple Sclerosis Outcome Assessments Consortium.

Neurology. 2019 Nov 19;93(21):e1921-e1931. doi: 10.1212/WNL.0000000000008519. Epub 2019 Oct 22.

7.

Natalizumab wearing-off symptoms: Patients with MS on extended interval dosing may not "mind the gap".

Mowry EM, Bourdette D.

Neurology. 2019 Oct 22;93(17):735-736. doi: 10.1212/WNL.0000000000008358. Epub 2019 Sep 24. No abstract available.

PMID:
31551259
8.

Another sphingosine 1-phosphate receptor modulator for the treatment of patients with multiple sclerosis.

Mowry EM, Corboy JR.

Lancet Neurol. 2019 Nov;18(11):983-985. doi: 10.1016/S1474-4422(19)30333-3. Epub 2019 Sep 3. No abstract available.

PMID:
31492653
9.

Environmental and genetic risk factors for MS: an integrated review.

Waubant E, Lucas R, Mowry E, Graves J, Olsson T, Alfredsson L, Langer-Gould A.

Ann Clin Transl Neurol. 2019 Sep;6(9):1905-1922. doi: 10.1002/acn3.50862. Epub 2019 Aug 7. Review.

10.

The prevalence and utility of screening for urinary tract infection at the time of presumed multiple sclerosis relapse.

Fitzgerald KC, Cassard LA, Fox SR, Probasco JC, Cassard SD, Mowry EM.

Mult Scler Relat Disord. 2019 Oct;35:61-66. doi: 10.1016/j.msard.2019.06.038. Epub 2019 Jul 2.

PMID:
31344604
11.

Early complement genes are associated with visual system degeneration in multiple sclerosis.

Fitzgerald KC, Kim K, Smith MD, Aston SA, Fioravante N, Rothman AM, Krieger S, Cofield SS, Kimbrough DJ, Bhargava P, Saidha S, Whartenby KA, Green AJ, Mowry EM, Cutter GR, Lublin FD, Baranzini SE, De Jager PL, Calabresi PA.

Brain. 2019 Sep 1;142(9):2722-2736. doi: 10.1093/brain/awz188.

PMID:
31289819
12.

Multiple Sclerosis Risk Factors and Pathogenesis.

Nourbakhsh B, Mowry EM.

Continuum (Minneap Minn). 2019 Jun;25(3):596-610. doi: 10.1212/CON.0000000000000725. Review.

PMID:
31162307
13.

Multiple Sclerosis Performance Test: Technical Development and Usability.

Rhodes JK, Schindler D, Rao SM, Venegas F, Bruzik ET, Gabel W, Williams JR, Phillips GA, Mullen CC, Freiburger JL, Mourany L, Reece C, Miller DM, Bethoux F, Bermel RA, Krupp LB, Mowry EM, Alberts J, Rudick RA.

Adv Ther. 2019 Jul;36(7):1741-1755. doi: 10.1007/s12325-019-00958-x. Epub 2019 May 3.

14.

Retinal measurements predict 10-year disability in multiple sclerosis.

Rothman A, Murphy OC, Fitzgerald KC, Button J, Gordon-Lipkin E, Ratchford JN, Newsome SD, Mowry EM, Sotirchos ES, Syc-Mazurek SB, Nguyen J, Caldito NG, Balcer LJ, Frohman EM, Frohman TC, Reich DS, Crainiceanu C, Saidha S, Calabresi PA.

Ann Clin Transl Neurol. 2019 Jan 19;6(2):222-232. doi: 10.1002/acn3.674. eCollection 2019 Feb.

15.

Trial of intrathecal rituximab in progressive multiple sclerosis patients with evidence of leptomeningeal contrast enhancement.

Bhargava P, Wicken C, Smith MD, Strowd RE, Cortese I, Reich DS, Calabresi PA, Mowry EM.

Mult Scler Relat Disord. 2019 May;30:136-140. doi: 10.1016/j.msard.2019.02.013. Epub 2019 Feb 11.

PMID:
30771580
16.

Effect of disease-modifying therapies on subcortical gray matter atrophy in multiple sclerosis.

Sotirchos ES, Gonzalez-Caldito N, Dewey BE, Fitzgerald KC, Glaister J, Filippatou A, Ogbuokiri E, Feldman S, Kwakyi O, Risher H, Crainiceanu C, Pham DL, Van Zijl PC, Mowry EM, Reich DS, Prince JL, Calabresi PA, Saidha S.

Mult Scler. 2020 Mar;26(3):312-321. doi: 10.1177/1352458519826364. Epub 2019 Feb 11.

PMID:
30741108
17.

Validation of the SymptoMScreen with performance-based or clinician-assessed outcomes.

Fitzgerald KC, Salter A, Tyry T, Fox RJ, Cutter G, Mowry EM, Marrie RA.

Mult Scler Relat Disord. 2019 Apr;29:86-93. doi: 10.1016/j.msard.2019.01.031. Epub 2019 Jan 24.

PMID:
30690340
18.

Dimethyl fumarate treatment induces lipid metabolism alterations that are linked to immunological changes.

Bhargava P, Fitzgerald KC, Venkata SLV, Smith MD, Kornberg MD, Mowry EM, Haughey NJ, Calabresi PA.

Ann Clin Transl Neurol. 2018 Oct 30;6(1):33-45. doi: 10.1002/acn3.676. eCollection 2019 Jan.

19.

Spinal cord and infratentorial lesions in radiologically isolated syndrome are associated with decreased retinal ganglion cell/inner plexiform layer thickness.

Filippatou A, Shoemaker T, Esch M, Qutab M, Gonzalez-Caldito N, Prince JL, Mowry EM, Calabresi PA, Saidha S, Sotirchos ES.

Mult Scler. 2019 Dec;25(14):1878-1887. doi: 10.1177/1352458518815597. Epub 2018 Dec 3.

PMID:
30507269
20.

Body mass index, but not vitamin D status, is associated with brain volume change in MS.

Mowry EM, Azevedo CJ, McCulloch CE, Okuda DT, Lincoln RR, Waubant E, Hauser SL, Pelletier D.

Neurology. 2018 Dec 11;91(24):e2256-e2264. doi: 10.1212/WNL.0000000000006644. Epub 2018 Nov 14.

21.

Multiple sclerosis relapse: Qualitative findings from clinician and patient interviews.

Matza LS, Kim K, Phillips G, Zorn K, Chan KS, Smith KC, Mowry EM.

Mult Scler Relat Disord. 2019 Jan;27:139-146. doi: 10.1016/j.msard.2018.09.029. Epub 2018 Sep 26.

PMID:
30384199
22.

We need to conduct clinical trials of disease-modifying therapy in pregnancy to optimize care of women with MS - Yes.

Alvarez E, Mowry EM.

Mult Scler. 2019 Feb;25(2):187-188. doi: 10.1177/1352458518794061. Epub 2018 Oct 22. No abstract available.

PMID:
30346221
23.

Brain and retinal atrophy in African-Americans versus Caucasian-Americans with multiple sclerosis: a longitudinal study.

Caldito NG, Saidha S, Sotirchos ES, Dewey BE, Cowley NJ, Glaister J, Fitzgerald KC, Al-Louzi O, Nguyen J, Rothman A, Ogbuokiri E, Fioravante N, Feldman S, Kwakyi O, Risher H, Kimbrough D, Frohman TC, Frohman E, Balcer L, Crainiceanu C, Van Zijl PCM, Mowry EM, Reich DS, Oh J, Pham DL, Prince J, Calabresi PA.

Brain. 2018 Nov 1;141(11):3115-3129. doi: 10.1093/brain/awy245.

24.

Incorporating machine learning approaches to assess putative environmental risk factors for multiple sclerosis.

Mowry EM, Hedström AK, Gianfrancesco MA, Shao X, Schaefer CA, Shen L, Bellesis KH, Briggs FBS, Olsson T, Alfredsson L, Barcellos LF.

Mult Scler Relat Disord. 2018 Aug;24:135-141. doi: 10.1016/j.msard.2018.06.009. Epub 2018 Jun 23.

PMID:
30005356
25.

Effect of intermittent vs. daily calorie restriction on changes in weight and patient-reported outcomes in people with multiple sclerosis.

Fitzgerald KC, Vizthum D, Henry-Barron B, Schweitzer A, Cassard SD, Kossoff E, Hartman AL, Kapogiannis D, Sullivan P, Baer DJ, Mattson MP, Appel LJ, Mowry EM.

Mult Scler Relat Disord. 2018 Jul;23:33-39. doi: 10.1016/j.msard.2018.05.002. Epub 2018 May 5.

26.

The Evidence for Dietary Interventions and Nutritional Supplements as Treatment Options in Multiple Sclerosis: a Review.

Mische LJ, Mowry EM.

Curr Treat Options Neurol. 2018 Mar 17;20(4):8. doi: 10.1007/s11940-018-0494-5. Review.

PMID:
29549521
27.

A review of vitamin D supplementation as disease-modifying therapy.

Shoemaker TJ, Mowry EM.

Mult Scler. 2018 Jan;24(1):6-11. doi: 10.1177/1352458517738131. Review.

PMID:
29307295
28.

Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria.

Thompson AJ, Banwell BL, Barkhof F, Carroll WM, Coetzee T, Comi G, Correale J, Fazekas F, Filippi M, Freedman MS, Fujihara K, Galetta SL, Hartung HP, Kappos L, Lublin FD, Marrie RA, Miller AE, Miller DH, Montalban X, Mowry EM, Sorensen PS, Tintoré M, Traboulsee AL, Trojano M, Uitdehaag BMJ, Vukusic S, Waubant E, Weinshenker BG, Reingold SC, Cohen JA.

Lancet Neurol. 2018 Feb;17(2):162-173. doi: 10.1016/S1474-4422(17)30470-2. Epub 2017 Dec 21. Review.

PMID:
29275977
29.

The Dynamics of the Gut Microbiome in Multiple Sclerosis in Relation to Disease.

Mowry EM, Glenn JD.

Neurol Clin. 2018 Feb;36(1):185-196. doi: 10.1016/j.ncl.2017.08.008. Review.

PMID:
29157399
30.

Metabolic alterations in multiple sclerosis and the impact of vitamin D supplementation.

Bhargava P, Fitzgerald KC, Calabresi PA, Mowry EM.

JCI Insight. 2017 Oct 5;2(19). pii: 95302. doi: 10.1172/jci.insight.95302.

31.

The MSOAC approach to developing performance outcomes to measure and monitor multiple sclerosis disability.

LaRocca NG, Hudson LD, Rudick R, Amtmann D, Balcer L, Benedict R, Bermel R, Chang I, Chiaravalloti ND, Chin P, Cohen JA, Cutter GR, Davis MD, DeLuca J, Feys P, Francis G, Goldman MD, Hartley E, Kapoor R, Lublin F, Lundstrom G, Matthews PM, Mayo N, Meibach R, Miller DM, Motl RW, Mowry EM, Naismith R, Neville J, Panagoulias J, Panzara M, Phillips G, Robbins A, Sidovar MF, Smith KE, Sperling B, Uitdehaag BM, Weaver J; Multiple Sclerosis Outcome Assessments Consortium (MSOAC).

Mult Scler. 2018 Oct;24(11):1469-1484. doi: 10.1177/1352458517723718. Epub 2017 Aug 11. Review.

32.

Recurrent natalizumab-related aseptic meningitis in a patient with multiple sclerosis.

Foley RW, Tagg NT, Schindler MK, Fenton KM, Reich DS, Cortese I, Mowry EM.

Mult Scler. 2017 Sep;23(10):1424-1427. doi: 10.1177/1352458517702533. Epub 2017 Jun 22.

33.

Follow-Up of Emergency Department MRI Scans Suggesting New Diagnosis of CNS Demyelination.

Pakpoor J, Saylor D, Izbudak I, Liu L, Mowry EM, Probasco J, Yousem DM.

AJR Am J Roentgenol. 2017 Jul;209(1):171-175. doi: 10.2214/AJR.16.17279. Epub 2017 May 2.

PMID:
28463541
34.

PML in natalizumab-treated multiple sclerosis: Modeling errors and risk miscalculations.

Mowry EM, McArthur JC.

Neurology. 2017 Mar 21;88(12):1110-1111. doi: 10.1212/WNL.0000000000003749. Epub 2017 Feb 22. No abstract available.

PMID:
28228562
35.

Wellness and multiple sclerosis: The National MS Society establishes a Wellness Research Working Group and research priorities.

Motl RW, Mowry EM, Ehde DM, LaRocca NG, Smith KE, Costello K, Shinto L, Ng AV, Sullivan AB, Giesser B, McCully KK, Fernhall B, Bishop M, Plow M, Casaccia P, Chiaravalloti ND.

Mult Scler. 2018 Mar;24(3):262-267. doi: 10.1177/1352458516687404. Epub 2017 Jan 12.

36.

Neuromyelitis optica unmasked by a spinal dural arteriovenous fistula.

Freund B, Mowry EM, McR, Levy M, Newsome SD.

J Neuroimmunol. 2016 Nov 15;300:18-20. doi: 10.1016/j.jneuroim.2016.10.005. Epub 2016 Oct 12.

PMID:
27806871
37.

Emergency Department MRI Scanning of Patients with Multiple Sclerosis: Worthwhile or Wasteful?

Pakpoor J, Saylor D, Izbudak I, Liu L, Mowry EM, Yousem DM.

AJNR Am J Neuroradiol. 2017 Jan;38(1):12-17. doi: 10.3174/ajnr.A4953. Epub 2016 Oct 6.

38.

Environmental and genetic factors in pediatric inflammatory demyelinating diseases.

Waubant E, Ponsonby AL, Pugliatti M, Hanwell H, Mowry EM, Hintzen RQ.

Neurology. 2016 Aug 30;87(9 Suppl 2):S20-7. doi: 10.1212/WNL.0000000000003029. Review.

PMID:
27572857
39.

Long-term evolution of multiple sclerosis disability in the treatment era.

University of California, San Francisco MS-EPIC Team:, Cree BA, Gourraud PA, Oksenberg JR, Bevan C, Crabtree-Hartman E, Gelfand JM, Goodin DS, Graves J, Green AJ, Mowry E, Okuda DT, Pelletier D, von Büdingen HC, Zamvil SS, Agrawal A, Caillier S, Ciocca C, Gomez R, Kanner R, Lincoln R, Lizee A, Qualley P, Santaniello A, Suleiman L, Bucci M, Panara V, Papinutto N, Stern WA, Zhu AH, Cutter GR, Baranzini S, Henry RG, Hauser SL.

Ann Neurol. 2016 Oct;80(4):499-510. doi: 10.1002/ana.24747. Epub 2016 Aug 13.

40.

Haematopoietic stem cell transplants should be a second-line therapy for highly active MS - Commentary.

Mowry EM.

Mult Scler. 2016 Sep;22(10):1263-5. doi: 10.1177/1352458516660206. Epub 2016 Jul 21. No abstract available.

PMID:
27444561
41.

Association of Autoimmune Encephalitis With Combined Immune Checkpoint Inhibitor Treatment for Metastatic Cancer.

Williams TJ, Benavides DR, Patrice KA, Dalmau JO, de Ávila AL, Le DT, Lipson EJ, Probasco JC, Mowry EM.

JAMA Neurol. 2016 Aug 1;73(8):928-33. doi: 10.1001/jamaneurol.2016.1399.

PMID:
27271951
42.

Emerging Concepts on the Gut Microbiome and Multiple Sclerosis.

Glenn JD, Mowry EM.

J Interferon Cytokine Res. 2016 Jun;36(6):347-57. doi: 10.1089/jir.2015.0177. Epub 2016 May 4. Review.

43.

High consumption of coffee is associated with decreased multiple sclerosis risk; results from two independent studies.

Hedström AK, Mowry EM, Gianfrancesco MA, Shao X, Schaefer CA, Shen L, Olsson T, Barcellos LF, Alfredsson L.

J Neurol Neurosurg Psychiatry. 2016 May;87(5):454-60. doi: 10.1136/jnnp-2015-312176. Epub 2016 Mar 3.

44.

Genetic predictors of relapse rate in pediatric MS.

Graves JS, Barcellos LF, Shao X, Noble J, Mowry EM, Quach H, Belman A, Casper TC, Krupp LB, Waubant E; U.S. Network of Pediatric MS Centers.

Mult Scler. 2016 Oct;22(12):1528-1535. Epub 2016 Jan 14.

45.

Safety and immunologic effects of high- vs low-dose cholecalciferol in multiple sclerosis.

Sotirchos ES, Bhargava P, Eckstein C, Van Haren K, Baynes M, Ntranos A, Gocke A, Steinman L, Mowry EM, Calabresi PA.

Neurology. 2016 Jan 26;86(4):382-90. doi: 10.1212/WNL.0000000000002316. Epub 2015 Dec 30.

46.

Evidence for the Importance of Vitamin D Status in Neurologic Conditions.

Yeshokumar AK, Saylor D, Kornberg MD, Mowry EM.

Curr Treat Options Neurol. 2015 Dec;17(12):51. doi: 10.1007/s11940-015-0380-3.

PMID:
26538263
47.

Vitamin D in clinically isolated syndrome: evidence for possible neuroprotection.

Mowry EM, Pelletier D, Gao Z, Howell MD, Zamvil SS, Waubant E.

Eur J Neurol. 2016 Feb;23(2):327-32. doi: 10.1111/ene.12844. Epub 2015 Oct 31.

PMID:
26518224
48.

Multiple sclerosis patients have a diminished serologic response to vitamin D supplementation compared to healthy controls.

Bhargava P, Steele SU, Waubant E, Revirajan NR, Marcus J, Dembele M, Cassard SD, Hollis BW, Crainiceanu C, Mowry EM.

Mult Scler. 2016 May;22(6):753-60. doi: 10.1177/1352458515600248. Epub 2015 Aug 18.

49.

Magnetic resonance imaging correlates of clinical outcomes in early multiple sclerosis.

Maghzi AH, Revirajan N, Julian LJ, Spain R, Mowry EM, Liu S, Jin C, Green AJ, McCulloch CE, Pelletier D, Waubant E.

Mult Scler Relat Disord. 2014 Nov;3(6):720-7. doi: 10.1016/j.msard.2014.07.003. Epub 2014 Jul 23.

PMID:
25891551
50.

Effects of rituximab on lymphocytes in multiple sclerosis and neuromyelitis optica.

Graves J, Vinayagasundaram U, Mowry EM, Matthews IR, Marino JA, Cheng J, Waubant E.

Mult Scler Relat Disord. 2014 Mar;3(2):244-52. doi: 10.1016/j.msard.2013.10.003. Epub 2013 Oct 25.

PMID:
25878012

Supplemental Content

Support Center